View in EDS

Asthma and rhinitis control in adolescents and young adults: A real‐world MASK‐air study.

Saved in:
Bibliographic Details
Title: Asthma and rhinitis control in adolescents and young adults: A real‐world MASK‐air study.
Authors: Sousa‐Pinto, Bernardo, Valiulis, Arunas, Melén, Erik, Koppelman, Gerard H., Papadopoulos, Nikolaos G., Makela, Mika, Haahtela, Tari, Bonini, Matteo, Braido, Fulvio, Brussino, Luisa, Cruz, Alvaro A., Fiocchi, Alessandro, Giovannini, Mattia, Gemicioglu, Bilun, Kulus, Marek, Kuna, Piotr, Kupczyk, Maciej, Kvedariene, Violeta, Larenas‐Linnemann, Désirée E., Louis, Renaud
Source: Pediatric Allergy & Immunology; Feb2024, Vol. 35 Issue 2, p1-14, 14p
Subject Terms: YOUNG adults, ADOLESCENCE, RHINITIS, DEMOGRAPHIC characteristics, TEENAGERS, ALLERGIC conjunctivitis
Abstract: Background: In allergic rhinitis and asthma, adolescents and young adult patients are likely to differ from older patients. We compared adolescents, young adults and adults on symptoms, control levels, and medication adherence. Methods: In a cross‐sectional study (2015–2022), we assessed European users of the MASK‐air mHealth app of three age groups: adolescents (13–18 years), young adults (18–26 years), and adults (>26 years). We compared them on their reported rhinitis and asthma symptoms, use and adherence to rhinitis and asthma treatment and app adherence. Allergy symptoms and control were assessed by means of visual analogue scales (VASs) on rhinitis or asthma, the combined symptom‐medication score (CSMS), and the electronic daily control score for asthma (e‐DASTHMA). We built multivariable regression models to compare symptoms or medication accounting for potential differences in demographic characteristics and baseline severity. Results: We assessed 965 adolescent users (15,252 days), 4595 young adults (58,161 days), and 15,154 adult users (258,796 days). Users of all three age groups displayed similar app adherence. In multivariable models, age groups were not found to significantly differ in their adherence to rhinitis or asthma medication. These models also found that adolescents reported lower VAS on global allergy, ocular, and asthma symptoms (as well as lower CSMS) than young adults and adults. Conclusions: Adolescents reported a better rhinitis and asthma control than young adults and adults, even though similar medication adherence levels were observed across age groups. These results pave the way for future studies on understanding how adolescents control their allergic diseases. [ABSTRACT FROM AUTHOR]
Copyright of Pediatric Allergy & Immunology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
Description
Abstract:Background: In allergic rhinitis and asthma, adolescents and young adult patients are likely to differ from older patients. We compared adolescents, young adults and adults on symptoms, control levels, and medication adherence. Methods: In a cross‐sectional study (2015–2022), we assessed European users of the MASK‐air mHealth app of three age groups: adolescents (13–18 years), young adults (18–26 years), and adults (>26 years). We compared them on their reported rhinitis and asthma symptoms, use and adherence to rhinitis and asthma treatment and app adherence. Allergy symptoms and control were assessed by means of visual analogue scales (VASs) on rhinitis or asthma, the combined symptom‐medication score (CSMS), and the electronic daily control score for asthma (e‐DASTHMA). We built multivariable regression models to compare symptoms or medication accounting for potential differences in demographic characteristics and baseline severity. Results: We assessed 965 adolescent users (15,252 days), 4595 young adults (58,161 days), and 15,154 adult users (258,796 days). Users of all three age groups displayed similar app adherence. In multivariable models, age groups were not found to significantly differ in their adherence to rhinitis or asthma medication. These models also found that adolescents reported lower VAS on global allergy, ocular, and asthma symptoms (as well as lower CSMS) than young adults and adults. Conclusions: Adolescents reported a better rhinitis and asthma control than young adults and adults, even though similar medication adherence levels were observed across age groups. These results pave the way for future studies on understanding how adolescents control their allergic diseases. [ABSTRACT FROM AUTHOR]
ISSN:09056157
DOI:10.1111/pai.14080